• 1
    American Cancer Society. Cancer statistics, 1990. CA 1990.
  • 2
    Balsch CM, Mettlin C. Melanoma in the United States: A national survey of 4800 patients. In: BalchCM, MiltonGW, eds. Cutaneous Melanoma: Clinical Management and Treatment Results Worldwide. Philadelphia: J.B. Lippincott, 1985; 389395.
  • 3
    Bystryn J-C. Vaccine immunotherapy of melanoma. In: Human Melanoma: From Basic Research to Clinical Application. FerroneS, ed. Berlin: Springer-Verlag, 1990; 513530.
  • 4
    Bystryn J-C. Tumor vaccines. Cancer Metastasis Rev (in press).
  • 5
    Bystryn J-C. Antibody response and tumor growth in syngeneic mice immunized to partially purified B16 melanoma-associated antigens. J Immunol 1978; 120: 96101.
  • 6
    Avent J, Vervaert C, Seigler HF. Non-specific and specific active immunotherapy in a B16 murine melanoma system. J Surg Oncol 1979; 12: 8796.
  • 7
    Livingston PO, Calves MJ, Natoli EJ. Aphes to augmenting the immunogenicity of the ganglioside GM2 in mice, purified GM2 is superior to whole cells. J Immunol 1987; 138: 15241529.
  • 8
    Bystryn J-C, Jacobsen S, Harris M. Preparation and characterization of a polyvalent human melanoma antigen vaccine. J Biol Response Mod 1986; 5: 211224.
  • 9
    Berd D, MaGuire HC Jr, Mastrangelo MJ. Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. Cancer Res 1986; 46: 25722577.
  • 10
    Livingston PO, Natoli EJ, Calves MJ. Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients. Proc Natl Acad Sci U S A 1986; 84: 29112915.
  • 11
    Seigler HF, Cox E, Mutzner F et al. Specific active immunotherapy for melanoma. Ann Surg 1979; 100: 366372.
  • 12
    Wallack MK, Bash JA, Leftheriotis E et al. Positive relationship of clinical and serologic responses to vaccinia melanoma oncolysate. Arch Surg 1987; 122: 14601463.
  • 13
    Hersey P, Edwards A, Coates A et al. Evidence that treatment with vaccinia melanoma cell lysates (VMCL) may improve survival of patients with stage II melanoma: Treatment of stage II melanoma with viral lysates. Cancer Immunol Immunother 1987; 25: 257265.
  • 14
    Bystryn J-C, Oratz R, Harris MN et al. Immunogenicity of a polyvalent melanoma antigen vaccine in man. Cancer 1988; 61: 10651070.
  • 15
    Mitchell MS, Kan-Mitchell J, Kempf RA, Harel W, Shau H, Lind S. Active specific immunotherapy for melanoma: Phase I trial of allogeneic lysates and a novel adjuvant. Cancer Res 1988; 48: 58835893.
  • 16
    Pucetti P, Romani L, Fioretti MC. Chemical xenogenization of experimental tumors. Cancer Metastasis Rev 1987; 6: 93111.
  • 17
    Von Hoegen P, Weber E, Schirrmacher V. Modification of tumor cells by a low dose of Newcastle disease virus: Augmentation of the tumor-specific T cell responses in the absence of an antiviral response. Eur J Immunol 1988; 18: 11591166.
  • 18
    Bystryn J-C, Jacobsen JS, Liu P, Heaney-Kieras J. Comparison of cell-surface human melanoma-associated antigens identified by rabbit and murine antibodies. Hybridoma 1982; 1: 465472.
  • 19
    Heaney-Kieras J, Bystryn J-C. Identification and purification of a 75k-dalton cell-surface human melanoma associated antigen. Cancer Res 1982; 42: 23102319.
  • 20
    Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol 1983; 1: 710719.
  • 21
    Bystryn J-C, Bernstein P, Liu P, Valentine F. Immunophenotype of human melanoma cells in different metastases. Cancer Res 1985; 45: 17721777.
  • 22
    Bystryn J-C, Valentine F, Bernstein P. Tumor antigen heterogeneity and the specific immunotherapy of melanoma. In: BagnanaJ, KlausSW, PaulE, SchantlM, eds. Biological Molecular and Clinical Aspects of Pigmentation. Tokyo: University of Tokyo Press, 1985; 391396.
  • 23
    Livingston PO, Albino AP, Chung TJC et al. Serological response of melanoma patients to vaccines prepared from VSV lysates of autologous and allogenic melanoma cells. Cancer 1985; 55: 713720.
  • 24
    Mahaley MS Jr, Gillespie GY, Gillespie RP et al. Immunobiology of primary intracranial tumors: VIII. Serological responses to active immunization of patients with anaplastic gliomas. J Neurosurg 1983; 59: 208216.
  • 25
    Oratz R, Cockerall C, Speyer J, Harris MN, Roses DF, Bystryn JC. Induction of lymphocytic cell infiltrate in malignant melanoma metastases by immunization to melanoma antigen vaccine. J Biol Response Mod 1989; 8: 355358.
  • 26
    Bystryn J-C, Dugan M, Oratz R, Speyer J, Harris MN, Roses DF. Vaccine immunotherapy of human malignant melanoma: Relationship between method of immunization, immunogenicity, and tumor progression. In: FoxCF, ed. Human Tumor Antigens and Specific Tumor Therapy. New York: Alan R. Liss, 1989; 307315.
  • 27
    Bystryn J-C, Li J, Henn M, Oratz R. Identification of immunogenic antigens in a polyvalent melanoma antigen vaccine. Proc Am Assoc Cancer Res 1990; 31: 280.
  • 28
    Li J, Henn M, Oratz R, Bystryn J-C. The antibody response to immunization to a polyvalent melanoma antigen vaccine. Clin Res 1990; 38: 660A.
  • 29
    Reisfeld RA, David GS, Ferrone S, Pellegrino MA, Holmes EC. Approaches for the isolation of biologically functional tumor-associated antigens. Cancer Res 1977; 37: 28602865.
  • 30
    Bystryn J-C. Shedding and degradation of cell-surface macro-molecules and tumor-associated antigens by human melanoma. In: ReisfeldRA, FerroneS, eds. Melanoma Antigens and Antibodies. New York: Plenum Press, 1982; 3752.
  • 31
    Balch CM, Murad TQ, Soong SJ et al. A multifactorial analysis of melanoma: Prognostic histopathological features comparing Clark's and Breslow's staging methods. Ann Surg 1978; 188: 732742.
  • 32
    Veronesi U, Adamus J, Aubert C et al. A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. N Engl J Med 1982; 307: 913916.
  • 33
    Sterchi JM, Wells HB, Case LD et al. A randomized trial of adjuvant chemotherapy and immunotherapy in stage I and II cutaneous melanoma: An interim report. Cancer 1985; 55: 707712.
  • 34
    Berdeaux DH, Meyskens FL Jr, Parks B et al. Cutaneous malignant melanoma: II. The natural history and prognostic factors influencing the development of stage II disease. Cancer 1989; 63: 14301436.